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We report the conversion of a non-cytotoxic atibody-ricin A chain conjugate to one displaying specific 
cytotoxic effects comparable with that of native ricin, by the addition of ricin B chain as a second stage 
reagent. The results uggest that this conversion is achieved by the association of the added B chain with 
the A chain of the conjugate, and not through a primary binding of B chain at the cell surface. 
Rick A chain Targeting 
1. INTRO~UCTXO~ 
In the pursuit of antibody-directed chemo- 
therapy various expedients have been adopted, one 
of which has involved conjugation of plant toxins 
to antibodies [1,2]. Such conjugates generally mani- 
fest non-specific c~otoxicity due to the intrinsic 
binding capacity of the B piece of the toxins. This 
toxicity may be overcome by the use of antibody- 
toxin A chain conjugates. Such conjugates can in 
some cases be effective but in other instances the 
antibody moiety seems unable to act as a surrogate 
B chain and permit entry of A chain to the cytosof 
131. 
2. MATERIALS AND METHODS 
The tumour cell line HSNtc was derived from a 
benzpyrene-induced fibrosarcoma in hooded rats 
[4) and maintained in tissue culture in DMEM with 
5% foetal calf serum and 10% COZ; 1 I/l60 is a rat 
IgG2b monoclonal antibody specific for HSNtc 
that was obtained by fusion of the rat myeloma 
(Y3 Ag.1.2.3) with spleen cells from a rat bearing 
the HSNtc tumour 151. A conjugate of the struc- 
ture II/ t 60-NH-CO. CHKNz-SS-ricin A was pre- 
pared as in 161. 
Fig.i and table 1 show that these exposures had 
no effect on the level of protein synthesis and that 
the conjugate was even less toxic than the un- 
conjugated A chain. 
Thus, while the conjugate bound to its receptor 
on the target cells it seemed that this particular 
receptor was not permissive for entry of the A 
chain into the cytoplasm. Ricin B chain was pre- 
pared by reduction of the holotoxin and separation 
of the constituent peptides by chromatofocussing, 
The preparation was devoid of cytotoxic activity 
and was investigated as a second stage reagent for 
potentiation of the A chain conjugate activity. 
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The capacity of the A chain to inhibit ribosomai 
protein synthesis after conjugation to the antibody 
was assayed in a rabbit reticulocyte cell-free system 
[7] and found to be unimpaired. Binding of the 
conjugate was assessed by the measurement of iz51- 
labelled sheep anti-rat y 2 on the target cells. 
The facility of the conjugate to inhibit protein 
synthesis in the target cell population was assayed 
by measuring 13H]leucine incorporation into cellu- 
lar protein after l-h and 24-h exposures of con- 
jugate to the cells. 
3. RESULTS AND DISCUSSION 
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Fig.1. Specific cytotoxic effects of ricin A chain conju- 
gated to monoclonal 1 l/J60 antibody, on HSNtc cells in 
tissue culture. The cells were plated out at 2 x 10’ ml-’ 
in 24 well plates for 24 h prior to incubation for 1 h at 
37°C with 111160~SS-ricin A (a), ricin A (o), I l/l60 
(A) and II/l60 -t ricin A (0) in Dulbecco’s modifica- 
tion of Eagle’s medium (~MEM) supplemented with 
10% heat-inactivated foetal calf serum and antibiotics. 
Cells were then washed in DMEM (but without toxin A 
chain and antibody) and incubated at 37°C in fresh 
culture medium for 27 h. Each well was then pulsed with 
l&i 13H)leucine for 18 h before harvesting celluiar pro- 
tein and scintillation counting. The [3H]Ieucine incor- 
poration is expressed as a percentage of that in untreated 
control cultures which incorporated 43 006 cpm&-‘. 
Each data point represents the arithmetic mean of 3 
determinations, the standard deviations of which are 
indicated by vertical lines unless smaller than the points 
as plotted. 
Fig.2 shows the potent cytotoxic effect obtained 
when binding of 1 l/160-SS-ricin A to HSNtc cells 
for I h was folowed by a I-h treatment with ricin 
Table 1 
The effects of ricin, its isolated A and B chains and ricin A chain conjugates on HSNtc cells 
Treatment 1 
Ricin 1 h 
Ricin + lactose 1 h 
Ricin 1 h 
Ricin B 1 h 
Ricin A 1 h 
Ricin A 24 h 
1 l/160-r~cin-A 1 h 
1 l/160-ricin-A 24 h 
ll/l~-ricin-A 1 h 
1 l/l~-ricin-A I h 
MlOiWricin A 
Treatment 2 
- 
_ 
6 x lactose wash 
- 
- 
ricin B chain 1 h 
ricin B chain + Lactose I h 
ricin B chain 1 h 
10,&l ricin A) 
1.1 x lo-r2 
2.4 x lo-i0 
1.1 x lo-” 
> lo-’ 
> lo-? 
5 X 10-s 
no effect at IO-’ 
no effect at 10e7 
3.2 x lo-r2 
5.3 x lo-‘2 
3 lo-’ 
Rick A 1 h 
Ricin A 1 h 
Ricin B I h 
Ricin B 1 h 
Ricin B f lactose 1 h 
Ricin B 
Riein B 
ricin B 1 h 
ricin B + lactose I h 
ricin A 1 h 
ricin A +lactose 1 h 
ricin A chain 
MlO/76-rick-A 1 h 
1 i/160-&in-A 1 h 
1 x lo-7 
>l x lo-’ 
2.6 x lo-” 
1.5 x 1o-9 
4.5 x 1o-9 
2.5 x 1o@0 
1 x lo-‘3 
The IDso is the dose required to inhibit the incorporation of [3Hjleucine into protein by 50%. 
HSNtc cells were plated out at 2 x 10’ ml-’ for 24 h prior to a l-h incubation at 37°C with 
materials listed in treatment 1. Cells were washed S-times in DMEM with 10% foetal calf 
serum and incubated for 1 h at 37°C with materials listed in treatment 2. The cells were then 
washed 3-times and incubated for 27 h in DMEM and pulsed with [3H]Ieucine as described 
(fig.1). All determinatjons were made in triplicate 
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Fig.2. Specific cytotoxic effects of ricin on HSNtc cells 
and of 11/160-SS-ricin A and M10/76-SS-ricin A fol- 
lowed by ricin B chain at lo-’ M. Cells were plated out 
as described (fig.1) and incubated for 1 h at 37°C with 
ricin (o), 1 l/160-SS-ricin A (m) or M10/76-SS-ricin A
(A) in DMEM with 10% foetal calf serum. The cells 
were washed in medium as before (fig.1) and the ricin- 
treated cells were incubated and pulsed as described. 
Cells treated with ricin A chain conjugates were then 
incubated for 1 h at 37°C with ricin B chain at lo-‘M 
after which they were washed 3-times in medium and 
incubated, pulsed and harvested as described (fig.1). 
B chain at lo-‘M. This is compared (fig.2) with 
the toxicity of whole ricin and a comparable treat- 
ment with an A chain conjugate with monoclonal 
antibody Ml0176 [5] which does not react with 
HSNtc cells. Treatment of another rat fibrosarcoma 
cell line, MC24 with 11/160-SS-ricin A followed by 
B chain resulted in no cytotoxic effect. Cytotoxic 
effects, expressed as Z&O’s are shown in table 1. 
The results obtained after preincubating HSNtc 
cells with B chain for 1 h prior to the addition of 
the specific and non-specific conjugates are also 
shown (table 1). 
There seemed two possible mechanisms whereby 
the inactivated 11/160 conjugate could be con- 
verted to a potent cytotoxin by the addition of B 
chain. It has been shown [8] that, following reduc- 
tion of the disulphide bond, the A and B subunits 
of ricin appear to be held together by weak, non- 
covalent interactions. Therefore, following binding 
of 1 l/160-SS-ricin-A to the cell surface, the addi- 
tion of B chain could result in an annealing of the 
ricin B chain with the A chain of the conjugate. 
This would lead to the formation of a quasi-holo- 
toxin conjugate at the cell surface. The second pos- 
sibility was that the B chain might bind to galactose 
residues at the cell surface and that this binding 
would act as a signal for the cell to internalise its 
membrane-bound ligands. 
Lactose at 1OOmM has been shown to compete 
with cellular galactose residues for the binding site 
of ricin B chain [9] and has been used to abrogate 
B chain binding of holotoxin conjugates to cellular 
carbohydrate receptors in in vitro bone marrow 
cleansing studies [lo]. Fig.3 shows that the Z&O of 
ricin on HSNtc cells is increased lOO-fold by the 
presence of 100 mM lactose in the incubation 
medium. The ZDSO of 1 l/160-SS-ricin-A when B 
chain is added in the presence of 100 mM lactose is 
unaffected. This result argues against the binding 
of B chain to cellular galactose residues as the 
potentiating mechanism, and supports the notion 
of B chain annealment o the A chain component 
of the conjugate. This interpretation is in agree- 
ment with the findings in [ 111. 
To test this hypothesis further, the interactions 
of isolated A and B chains as inhibitors of protein 
synthesis in the presence and absence of lactose 
have been investigated (table 1). Prior treatment of 
cells with lo-’ M ricin B chain followed by a 1 h in- 
cubation with ricin A chain resulted in the forma- 
tion of a cytotoxic product at the cell surface which 
is likely to be quasi-holotoxin since neither 1 h 
treatments with A or B chains result in any cyto- 
toxic effect. The presence of 100 mM lactose in- 
hibited the cytotoxic effect if the sugar was added: 
(i) during treatment with B chain by competing 
with the cell surface glycoproteins for the B chain 
binding sites; (ii) subsequently during addition of 
the A chain by the elution of a proportion of the 
surface-bound B chain. Lactose had no effect on 
the binding of 11/160-SS-ricin-A to HSNtc cells 
and did not inhibit the subsequent binding of B 
chain to this conjugate. We conclude from these 
results that by the addition of ricin B chain we have 
succeeded in eliciting a specific cytotoxic effect 
with a formerly inactive ricin A chain conjugate. 
The use of toxin B chains as potentiating agents 
may have immediate application for the in vitro 
eradication of tumour cells from bone marrow and 
it has been reported in [12] that the addition of 
ricin B chain can increase the efficiency of entry of 
A chain conjugates. The application of the two 
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treatments of this type in vivo, both of which are 
non-cytotoxic and which culminate in a cytotoxic 
event specified by the binding of the first stage 
monocIon~-antibody conjugate, has exciting im- 
plications for the treatment of tumours and their 
metastatic deposits. However, one might expect 
that the systemic introduction of ricin B via the cir- 
culation will be difficult to achieve due to its pro- 
pensity to bind galactose residues on plasma glyco- 
proteins, blood cells and vascular endothelium. 
Blockade of the galactose binding site, which the 
present experiments uggest is not important to the 
effectiveness of B chain as a second stage reagent, 
might be achievable by chemical modification of 
the peptide, the use of photoactivatable affinity 
labels or antibodies directed to binding site epi- 
topes. Some of these possibilities are being inves- 
tigated in vitro and in rats bearing the target 
tumour. 
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